Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Eric Dein ericdeinmd
3 years 1 month ago
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Novel Aspects
Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles
Microvasc - Suspected/Established
@RheumNow https://t.co/M8NWRSyH4p
Olga Petryna DrPetryna
3 years 1 month ago
#abs1235 #acr22 @rheumnow
articular fibroblast activation in PSO assessed by 68Ga-FAPI-04 PET-CT assoctd w/⬆️ risk of developing PsA. 10 pts assessed: 6/7 pts (85.7%)w/ 68Ga-FAPI-04 uptake at synovio-entheseal sites progressed to PsA. median PsA-free time 207 (160-240)days https://t.co/Y6EHPaDwfh
Dr. Rachel Tate uptoTate
3 years 1 month ago
PsA pts starting 1st DMARD tx, both early & late initiators experienced dz activity and PRO improvements up to 6 months post-initiation. Better response, including MDA, achieved in pts initiating DMARD tx w/in 1 yr of dx. Abs 1493 #ACRbest #ACR22 @RheumNow https://t.co/a94sZRQ3VF https://t.co/OSUEoChtFf
Patricia Harkins DrTrishHarkins
3 years 1 month ago
🌟PSA vs RA 🌟
-UK cohort
PSA associated with:
👉⬆️ duration symptoms prior 2 referral
👉⬆️ interval between GP presentation and DX
👉⬇️DMARD commencement
👉⬇️ improvement in Dx activity @ 3/12
# We need to do better
#ACR22 Abst#1613 @RheumNow
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Patients with PsA and AS who used opioids had higher healthcare utilization and higher costs. Also
➣ more comorbidities
➣ higher prevalence of smoking
➣ worse disease activity
➣ higher use of anti-rheumatic drugs
Ogdie A Abs0402 https://t.co/3E4qAuqgpI #ACR22 @RheumNow https://t.co/AaKxiQXMwx
Richard Conway RichardPAConway
3 years 1 month ago
Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb
David Liew drdavidliew
3 years 1 month ago
What are we treating PMR with?
RISE registry, 2016-20 (n=26,102 in US)
- Such a small proportion ever see non-steroid therapies
- Big chunk remain on steroids or lost to follow-up
Surely we can improve PMR care!
ABST1546 @SattuiSEMD @RADoctor #ACR22 @RheumNow https://t.co/Ocuw5WxKu2
TheDaoIndex KDAO2011
3 years 1 month ago
Don't stop HCQ even after ESRD occurs in #LupusNephritis!
1578 pts w/ESRD on HCQ only, GCs only or HCQ+GCs (n=509). HCQ groups had lower cardiac complications & infx compared to steroid only group. No diff. in thrombosis & all-cause mortality. #ACR22 @rheumnow #ACRbest abst#0539
Richard Conway RichardPAConway
3 years 1 month ago
Lee et al. 55% of requested cryoglobulin tests not successfully completed. @RheumNow #ACR22 Abstr#1281 https://t.co/QLCEFueeHi https://t.co/toEUukyXQf
Dr. Rachel Tate uptoTate
3 years 1 month ago
Higher NSAID intake is assoc'd w/ lower radiographic spinal progression, particularly in r-axSpA patients. COX2i might have stronger inhibitory effect on radiographic progression compared to NS-NSAIDs. @ProftDr @RheumNow Abs 1492 #ACR22 https://t.co/l51wMqm5fB https://t.co/UaBCRRSJEE
Patricia Harkins DrTrishHarkins
3 years 1 month ago
Subclinical GCA in PMR
🌟US findings of GCA in 22% PMR pts w/o signs or symptoms of GCA
🔥Different US pattern vs classical GCA
Subclinical GCA:
👉predilection extra-cranial arteries
👉⬆️ IMT of large vessels
#ACR22 @RheumNow Abst#1619 https://t.co/HV9dsTBfg8
Bella Mehta bella_mehta
3 years 1 month ago
Nurses’ Health Study - 34 yr f/u data #gout
- women with gout have ⬆️ risk of all-cause mortality,
- primarily driven by ⬆️ risk of CVD deaths.
#ACR22 @rheumnow abst#1757 https://t.co/K2ykelHAlL
Eric Dein ericdeinmd
3 years 1 month ago
13S150. Draft ACR/EULAR APLS Classif Criteria
⭐️Reminder: Classification = high specificity, not Diagnostic Crit!
⭐️Previously Sapporo: clinical (vasc/preg) + immunologic
-- Lack of risk stratification, unclear definition of aPL+, no valvulopathy, outdated pregnancy
@Rheumnow
Robert B Chao, MD doctorRBC
3 years 1 month ago
Izokibep, a new IL-17Ai, demonstrated efficacy in treatment of psoriatic arthritis in a phase 2 study with a safety profile similar to other IL-17i.
Abs#1597 @RheumNow #ACR22 https://t.co/3LA9u8NsC4
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Abstr#0957 Do women with Anti-Ro/La+ get 1st screening for congenital heart block via foetal echo in time (16-18 wks)? A cohort study in 44 pregnancies found only 32% had =<18wks. 5 CHB detected (3 in 1st screening which was >19wks. This needs to improve @RheumNow https://t.co/dqJCCSwGLx
Poster Hall